Go Pro
→ AI Panic: Sell now or wait? (From TradeSmith) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
$0.0003 0.00 (0.00%)
As of 09/23/2026
Compare

CALA vs. ADTX, CMRA, STAB, EVLO, and EFTR

Should you buy Calithera Biosciences stock or one of its competitors? Calithera Biosciences's main competitors and comparable companies include Aditxt (ADTX), Comera Life Sciences (CMRA), Statera Biopharma (STAB), Evelo Biosciences (EVLO), and eFFECTOR Therapeutics (EFTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calithera Biosciences compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Calithera Biosciences (NASDAQ:CALA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Aditxt has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Calithera Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Calithera Biosciences has lower revenue, but higher earnings than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.26-$41.71M-$100.79 thousandN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

15.5% of Aditxt shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aditxt had 1 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for Aditxt and 1 mentions for Calithera Biosciences. Calithera Biosciences' average media sentiment score of 0.00 beat Aditxt's score of -0.51 indicating that Calithera Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aditxt
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative
Calithera Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Calithera Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Calithera Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Calithera Biosciences N/A N/A N/A

Summary

Aditxt and Calithera Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Calithera Biosciences compare to Comera Life Sciences?

Calithera Biosciences (NASDAQ:CALA) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

In the previous week, Calithera Biosciences had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Comera Life Sciences. Calithera Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Calithera Biosciences has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Comera Life Sciences beats Calithera Biosciences on 3 of the 5 factors compared between the two stocks.

How does Calithera Biosciences compare to Statera Biopharma?

Calithera Biosciences (NASDAQ:CALA) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Statera BiopharmaN/AN/AN/AN/AN/A

In the previous week, Calithera Biosciences had 1 more articles in the media than Statera Biopharma. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Statera Biopharma. Calithera Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Statera Biopharma Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

Calithera Biosciences has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Summary

Calithera Biosciences beats Statera Biopharma on 2 of the 3 factors compared between the two stocks.

How does Calithera Biosciences compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Calithera Biosciences (NASDAQ:CALA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Calithera Biosciences had 1 more articles in the media than Evelo Biosciences. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Evelo Biosciences. Evelo Biosciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Calithera Biosciences Neutral

Evelo Biosciences has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Summary

Evelo Biosciences and Calithera Biosciences tied by winning 3 of the 6 factors compared between the two stocks.

How does Calithera Biosciences compare to eFFECTOR Therapeutics?

Calithera Biosciences (NASDAQ:CALA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Calithera Biosciences has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Calithera Biosciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for eFFECTOR Therapeutics. Calithera Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
eFFECTOR Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 4 of the 6 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net Income-$39.65M$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.69%-1.08%-0.11%
1 Month PerformanceN/A-1.10%-3.39%-3.42%
1 Year PerformanceN/A2.10%15.08%5.46%

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/A$0.00
flat		N/A+200.0%$1KN/AN/A60
ADTX
Aditxt
0.1508 of 5 stars		$0.01
-8.9%		N/A-100.0%$4K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
STAB
Statera Biopharma
N/A$0.00
flat		N/A-50.0%$3KN/AN/A20
EVLO
Evelo Biosciences
N/AN/AN/A-80.0%$2KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel